Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP450 vs Botox for Moderate to Severe Glabellar Lines
NCT06354127Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prabotulinumtoxinA in glabellar lines (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Response rate based on the investigator's on-site assessment of severity of glabellar lines at maximum frown at 4 weeks. Started Aug 2020; status: completed.
02
Drugs
prabotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06354127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354127.